Immunogen Inc. 830 Winter Street Waltham,
MA 02451 United States - Map Phone: 781-895-0600 Fax: 781-895-0611 Website: http://www.immunogen.com
ImmunoGen, Inc. engages in the research and development of targeted therapeutics for the treatment of cancer using cancer biology, monoclonal antibodies, and highly potent cell-killing agents. The company develops its products using its Targeted Antibody Payload (TAP) technology. Its product candidates include Trastuzumab emtansine (T-DM1), a Phase III clinical trial product for HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product, which targets CD56 found on small-cell lung cancer, Merkel cell carcinoma, multiple myeloma, ovarian cancers, carcinoid tumors, and other cancers of neuroendocrine origin; IMGN529, a pre-investigational new drug stage drug for CD37+ B-cell malignancies, such as non-Hodgkin's lymphoma; and IMGN853, a preclinical stage product for cancers that overexpress folate receptor 1, including ovarian cancer. The companys earlier-stage compounds in development stage comprise SAR3419, a Phase I clinical trial product for CD19+ B-cell malignancies, including non-Hodgkin's lymphoma; SAR650984, a Phase I clinical trial product for CD38+ hematological malignancies; SAR566658, a phase one clinical trial product for DS6+ solid tumors; and BT-062, a Phase I product for multiple myeloma. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. Key Statistics
| |
| Immunogen Inc.’s Governance Risk Indicator (GRI®) as of May 1, 2012 is: Audit (Low Concern), Board (Low Concern), Compensation (Low Concern), Shareholder Rights (Medium Concern). | | Brought to you by Institutional Shareholder Services (ISS) |
| | Pay | Exercised | Mr. Daniel M. Junius ,
60 Chief Exec. Officer, Pres and Director | 729.00K | 0.00 | Dr. John M. Lambert Ph.D.,
61 Exec. VP of R&D and Chief Scientific Officer | 484.00K | 0.00 | Mr. Craig Barrows ,
57 VP, Sec. and Gen. Counsel | 389.00K | 0.00 | Dr. James J. O'Leary M.D.,
48 Chief Medical Officer and VP | 469.00K | 0.00 | Ms. Carol Hausner ,
Exec. Director of Investor Relations and Corp. Communications | N/A | N/A |
|
| | Amounts are as of Dec 30, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|